**Core tip:** The available literature indicates that the immunological response to vaccines in children with celiac disease (CD) does not differ markedly from that of general population and antibody titres are high enough to provide long-term protection, except for hepatitis B virus (HBV) vaccine. Because the majority of persons with CD has the HLA-DQ2 haplotype, it has been hypothesized that such genetic profile could have an important part in predisposing CD subjects to a less degree of immunity following HBV vaccination. New vaccination strategies have been proposed to give protection to all of these CD patients.

INTRODUCTION
============

Celiac disease (CD) is an immune-mediated systemic condition evoked by ingestion of gluten and related prolamines in genetically susceptible subjects. The disease is featured by a variable combination of clinical signs and symptoms, specific antibodies, HLA-DQ2 and HLA-DQ8 haplotypes, and enteropathy. Genetic, immunological and environmental factors therefore appear to be accountable for the disorder. CD is strongly associated with HLA-DQ2 and HLA-DQ8. HLA-DQ2 is found in 90% to 95% of CD individuals, HLA-DQ8 haplotype in 5%, and at least one of the two DQ2 alleles in 5% of them\[[@B1],[@B2]\].

Vaccines have been, and continue to be, among the greatest public health achievement in history, and they are the most powerful measure for the prevention of infectious diseases\[[@B3]\]. They have lowered both morbidity and mortality from severe global infections such as diphtheria, pertussis, tetanus, measles, mumps, rubella, hepatitis B and others\[[@B4]\]. Several factors such as age, gender, ethnicity, quality and quantity of vaccine antigen, doses, and route of administration\[[@B5]\], can influence immune response to vaccine, although the main cause of variation in the responsiveness among vaccine recipients is host genetic variation\[[@B6]\]. Single nucleotide polymorphisms (SNPs) in human leukocyte antigen (HLA) class I and II, cytokine and their receptors, and innate immunity (*i.e*., toll-like receptor) genes have been hypothesized as responsible for the variability among individuals in protective immunity induced by vaccines, including neutralizing antibodies\[[@B7]\]. In particular, the HLA system has a fundamental role in identifying the antigens introduced into the host with the vaccines and in the development of specific antibodies\[[@B8],[@B9]\] and some HLA phenotypes have been associated with a less effective immunological response\[[@B10]\]. The available literature indicates that the immunological response to vaccines in children with CD does not differ markedly from that of general population and antibodies titres are high enough to provide long-term protection, except for hepatitis B virus (HBV)\[[@B11]-[@B24]\]. Although the mechanism for HBV vaccination failure in subjects with CD is unknown, a few hypotheses have been made. There has been advocated that HLA genotype DQ2 may predispose CD subjects to a lesser degree of immunization to recombinant HBV vaccine\[[@B11],[@B25]-[@B27]\]. HLA-DQ2 haplotype may be responsible for lack of induction of the Th2 response that is necessary for B cell differentiation and formation of memory B cells. Other authors have suggested that the response to HBV vaccination in individuals affected by CD may depend on disease activity and compliance to a gluten free diet (GFD)\[[@B12],[@B13],[@B15],[@B18]\]. Indeed, gluten consumption at the time of vaccination has been hypothesized as a cause of failure of immunity. Gluten may be implicated since both HBV surface antigen (HbsAg) protein fractions and gliadin peptides fasten to HLA-DQ2 particles and activate proliferation of T lymphocytes\[[@B12]\]. Contention between the proteins might lead to impaired antibody synthesis. In this article, we review and discuss the scarce literature on this field in order to provide clinical practice guidelines to achieve the most efficient monitoring of the response to vaccines in pediatric CD patients.

CELIAC DISEASE AND THE RISK OF INFECTIONS
=========================================

Several respiratory infections have been associated with CD in adults, such as invasive pneumococcal disease (*i.e*., pneumonia)\[[@B28]-[@B30]\], sepsis\[[@B31]\] , incident tuberculosis\[[@B32]\], and death resulting from tuberculosis\[[@B33]\]. In addition, children with CD have a higher risk of influenza infection and secondary hospital admission\[[@B21]\]. The increased infection risk in CD patients is probably due to several factors. Malnutrition or increased intestinal permeability associated with CD could be one of them. Defective nutritional status, that is frequent both in CD and in patients with subclinical disease as well as following the start of GFD\[[@B34]\], can result in lack of folate, vitamin B12, and in poor vitamin D status. Deficiency of folate and vitamin B12 are correlated with a decrease in immune-competence\[[@B35]\] and a higher burden of respiratory infections (including influenza)\[[@B36],[@B37]\], while poor vitamin D status\[[@B38]\] may result in the impairment of the defense mechanisms against respiratory pathogens and predispose to respiratory infections such as influenza and tuberculosis\[[@B39]\]. CD patients have increased intestinal mucosal permeability, but not only\[[@B40]\]: respiratory mucosal permeability is also increased\[[@B41]\], and this may facilitate the entry of influenza virus. Hyposplenism also occurs in CD, although this condition seems to be important only in adult cases of CD\[[@B42]\].

Thus, it is essential to implement a comprehensive vaccination program for CD patients with the available vaccines and to evaluate immunological response to these vaccines in CD patients.

RESPONSES TO VACCINATIONS IN CHILDREN WITH CELIAC DISEASE
=========================================================

There are few studies on the antibody response to vaccines of patients with CD. The majority relate to HBV, while very few reports are available on the immunological response to other vaccinations.

Some reports imply that celiac patients may have a low level of protective antibodies after HBV vaccination. The lack of response among CD subjects to HBV vaccination is important for public health policies because these non-responders may be a reservoir for HBV\[[@B43]\]. The published studies on the association between CD and HBV vaccination in children are presented in Table [1](#T1){ref-type="table"}\[[@B11]-[@B21],[@B24]\]. In the earliest report, involving 26 celiac patients aged 9.2 ± 4.6 years and 18 age-matched controls, receiving the full complement of childhood vaccination (HBV, tetanus, rubella, *Haemophilus influenzae* type b), Park et al\[[@B11]\] showed that a significantly greater percentage of children with CD did not respond to HBV vaccination in comparison with controls (53.9% *vs* 11.1%, *P* \< 0.05). However, all of the children responded to other vaccinations. These results led the authors to consider the importance of HLA haplotypes in the development of immunity to HBV vaccine. Nemes et al\[[@B12]\] evaluated HBV vaccine response in CD children in relation to disease activity, assessed by measuring serum antibody concentrations to transglutaminase, and dietary gluten in the failure to reach protective antibody titers. The authors studied 128 biopsy-proven CD children and adolescents and 113 age-matched controls: 22 patients with CD on GFD were prospectively given a recombinant HBV vaccine, while the remaining 106 CD patients received a recombinant HBV vaccine which was not related to the diagnosis of CD or compliance to GFD. They found that the rate of seroconversion for anti-HBs was 95.5% (95%CI: 78.25%-99.2%) in the patients prospectively immunized. However, for the other patients the response rate was 50.9% and was related to gluten consumption (youths on gluten-containing diet, 25.9%; patients non-compliant to GFD, 44.4%; patients on strict GFD, 61.4%). These results would suggest the importance of disease activity in vaccination failure rather than specific HLA alleles\[[@B12]\]. Subsequently, Ertem et al\[[@B13]\], evaluated serologically the anti-HBs status of 63 biopsy-proved CD patients on a strict GFD and 54 healthy children. CD youths with negative anti-HBs antibodies at baseline were reevaluated after full vaccination. The authors demonstrated that the seroconversion rate to HBV vaccine in CD patients was 96.9%, the same as that observed in the healthy population. It was concluded that GFD and compliance to diet, rather than the specific HLA alleles may increase the immune response to HBV vaccination in CD patients\[[@B13]\]. Balamtekın et al\[[@B14]\] compared the rates of seroconversion to HBV vaccine in the first year of life, utilizing two different immunization schedules. The entire study population consisted of 64 CD children (group 1 who received HBV vaccination at birth, at 2 mo and at 9-12 mo of life and group 2, at birth, 1 mo and 6 mo of life), and 49 healthy controls. The response rate to HBV vaccination as well as anti-HBs levels in CD children who completed the HBV vaccination were significantly lower than that of healthy controls, whereas no statistically significant difference was observed between the two different HBV vaccination schedules\[[@B14]\]. Similarly, Ertekin et al\[[@B15]\] evaluated the response to HBV vaccination in youths affected by CD compared to healthy children and examined the association between the patients' responses, the clinical signs of the disease, and compliance to GFD. They evaluated the production of specific anti-HBs surface antigen antibodies in 52 CD children and 20 controls matched for age and gender who received standard HBV vaccination. The authors found that 32 (61%) of CD patients had positive anti-HBs titers, while 18 (90%) of control subjects had positive anti-HBs titers. Among youths affected by CD, they also showed statistically significant differences between responders and non-responders with respect to clinical signs of the disease, and compliance to GFD (*P* \< 0.05). Thus, they concluded that, in children with CD, the immune response to HBV vaccination may be improved by compliance to GFD\[[@B15]\]. Leonardi et al\[[@B16]\] in a retrospective report confirmed that fewer CD patients respond to HBV vaccination than healthy subjects. Among 60 CD patients, they found that 30 (50%) were non-responders to HBV vaccination while 7 of 60 controls (11.6%) were non-responders. They also demonstrated that a significantly greater proportion of non-responders were adolescents older than 14 years, and concluded that very early diagnosis of CD increases the response rate to HBV vaccination. A short period of exposure to gluten appears, therefore, to have a favorable effect on the antibody memory\[[@B16]\]. In a subsequent retrospective study\[[@B17]\], the immunologic response against obligatory vaccination (HBV, diphteria and tetanus component and Bordetella pertussis) and against recommended vaccination (measles virus, paramyxoviridae and rubella virus) were compared in 66 CD patients and 50 healthy children. The authors found that the two groups responded similarly to obligatory and to recommended vaccines, except for HBV vaccine. Moreover, they compared children with a diagnosis of CD before and after 18 mo of age, and found that an early or a delayed diagnosis does not change the immunological response to vaccines, with the exception of HBV vaccination. Thus, the immunologic response would not appear to be affected by the natural history of CD\[[@B17]\]. Urgancy and Kalyoncu\[[@B18]\] determined the response rate to hepatitis A (HAV) and HBV vaccination, persistence of protection against HAV and HBV, and the occurrence of acute HAV or HBV infections during a period of follow-up in 30 children affected by CD in comparison with 50 healthy controls matched for age, sex, and body mass index\[[@B18]\]. They found natural immunity for HAV in 14 (46%) out 30 CD patients and 15 (30%) of the 50 controls, whereas none of the patients and controls showed evidence of earlier exposure to HBV. Sixteen of the patients and 35 of the controls were vaccinated with HAV; 12 of the sixteen patients and all the controls (75% *vs* 100%) developed anti-HAV antibodies. All of the 30 youths affected by CD and all of the 50 controls were vaccinated with HBV vaccine; 21 (70%) of the patients and 45 (90%) of the controls reached seroprotection. It was concluded that CD patients achieve a lower seroconversion rate to HBV and HAV vaccines than controls. Of note, there was a difference in GFD compliance between responders and nonresponders, though it was not statistically significant.

###### 

Immune response to vaccinations in youths with celiac disease

  **Ref**.                                                     **Year**                                     **Country**    **Study design**   **Patients population and sample size**                                                                                                    **Vaccine**   **Non responders**   **HLA**
  ------------------------------------------------------------ -------------------------------------------- -------------- ------------------ ------------------------------------------------------------------------------------------------------------------------------------------ ------------- -------------------- --------------------------
  Park et al\[[@B11]\]                                         2007                                         Japan          Prospective        26 (mean age ± SD, 9.2 ± 4.6 yr) untreated CD *vs* 18 (10.4 ± 3.8) controls                                                                HBV           53.90%               NA
                                                               *vs*                                                                                                                                                                                                                                                         
                                                               11.1%, *P* \< 0.05                                                                                                                                                                                                                                           
  RUBELLA                                                      0%                                                                                                                                                                                                                                                           
                                                               *vs*                                                                                                                                                                                                                                                         
                                                               0%                                                                                                                                                                                                                                                           
  TETANUS                                                      3.90%                                                                                                                                                                                                                                                        
                                                               *vs*                                                                                                                                                                                                                                                         
                                                               0%, *P* = 1.0                                                                                                                                                                                                                                                
  HIB                                                          33%                                                                                                                                                                                                                                                          
                                                               *vs*                                                                                                                                                                                                                                                         
                                                               44.4%, *P* = 0.53                                                                                                                                                                                                                                            
  Nemes et al\[[@B12]\]                                        2008                                         Finland        Prospective        22 (mean age, 8.8 yr) treated CD prospectively immunized; 27 (16.7 yr) untreated CD; 79 (16.7 yr) treated CD *vs* 113 (16.1 yr) controls   HBV           0.50%                Group 1 (22 treated CD):
  74.00%                                                       HLA DQ2                                                                                                                                                                                                                                                      
  38.60% *vs* 24.8%, *P* \< 0.001, *P* \< 0.001, *P* = 0.102   Group 2 (53/106 treated and untreated CD):                                                                                                                                                                                                                   
  51: HLA DQ2                                                                                                                                                                                                                                                                                                               
  2: HLA DQ8                                                                                                                                                                                                                                                                                                                
  Leonardi et al\[[@B16]\]                                     2009                                         Italy          Retrospective      60 (mean age, 9.32 yr) treated CD *vs* 60 (10.1 yr) controls                                                                               HBV           50%                  15/60:
  *vs*                                                         13 HLA-DQ2                                                                                                                                                                                                                                                   
  11.6%, *P* \< 0.0001                                         2 HLA-DQ8                                                                                                                                                                                                                                                    
  Ertem et al\[[@B13]\]                                        2010                                         Turkey         Retrospective      40 vaccinated (mean age ± SD, 12.4 ± 5.4 yr) treated CD *vs* 54 (9.8 ± 3.6 yr) controls                                                    HBV           32.50%               37.5% CD
  *vs*                                                         23.8% controls:                                                                                                                                                                                                                                              
  14.8%, *P* \< 0.05                                           HLA DRB1\*03                                                                                                                                                                                                                                                 
  Prospective                                                  28 prospectively vaccinated treated CD       3.60%          21% CD                                                                                                                                                                                           
  2.4% controls:                                                                                                                                                                                                                                                                                                            
  HLA DRB1\*07                                                                                                                                                                                                                                                                                                              
  55% CD                                                                                                                                                                                                                                                                                                                    
  14.6% controls:                                                                                                                                                                                                                                                                                                           
  HLA DQB1\*02                                                                                                                                                                                                                                                                                                              
  30% CD                                                                                                                                                                                                                                                                                                                    
  47.6% controls:                                                                                                                                                                                                                                                                                                           
  HLA DQB1\*03                                                                                                                                                                                                                                                                                                              
  Ertekin et al\[[@B15]\]                                      2011                                         Turkey         Retrospective      52 (mean age ± SD, 10.7 ± 4 yr) CD; *vs* 20 (10.7 ± 4 yr) controls                                                                         HBV           38.50%               NA
  *vs*                                                                                                                                                                                                                                                                                                                      
  10%, *P* \< 0.05                                                                                                                                                                                                                                                                                                          
  Balamtekın et al\[[@B14]\]                                   2011                                         Turkey         Retrospective      64 (mean age ± SD, 4.69 ± 2.31 yr) treated and untreated CD *vs* 49 (mean age 5.45 ± 2.92 yr) controls                                     HBV           21.90%               NA
  *vs*                                                                                                                                                                                                                                                                                                                      
  4.1%, *P* = 0.001                                                                                                                                                                                                                                                                                                         
  Urganci and Kalyoncu\[[@B18]\]                               2013                                         Turkey         Prospective        30 (mean age ± SD, 6.15 ± 4.1 yr) treated and untreated CD *vs* 50 ( 8.13 ± 1.7 yr) controls                                               HBV           30%                  NA
  *vs*                                                                                                                                                                                                                                                                                                                      
  10%, *P* = 0.03                                                                                                                                                                                                                                                                                                           
  Leonardi et al\[[@B17]\]                                     2011                                         Italy          Retrospective      66 (mean age ± SD, 8.34 ± 3.47 yr) CD, *vs* 50 (7.58 ± 3.51 yr) controls                                                                   HBV           53%                  NA
                                                               *vs*                                                                                                                                                                                                                                                         
                                                               16%, *P* \< 0.0001                                                                                                                                                                                                                                           
  POLIO                                                        100%                                                                                                                                                                                                                                                         
                                                               *vs*                                                                                                                                                                                                                                                         
                                                               100%, *P* = NS                                                                                                                                                                                                                                               
  DIPHTHERIA                                                   100%                                                                                                                                                                                                                                                         
                                                               *vs*                                                                                                                                                                                                                                                         
                                                               100%, *P* = NS                                                                                                                                                                                                                                               
  TETANUS                                                      100%                                                                                                                                                                                                                                                         
                                                               *vs*                                                                                                                                                                                                                                                         
                                                               100%, *P* = NS                                                                                                                                                                                                                                               
  MEASLE                                                       72%                                                                                                                                                                                                                                                          
                                                               *vs*                                                                                                                                                                                                                                                         
                                                               82%, *P* \< 0.0001                                                                                                                                                                                                                                           
  PAROTITIS                                                    81%                                                                                                                                                                                                                                                          
                                                               *vs*                                                                                                                                                                                                                                                         
                                                               92%, *P* = NS                                                                                                                                                                                                                                                
  RUBELLA                                                      81%                                                                                                                                                                                                                                                          
                                                               *vs*                                                                                                                                                                                                                                                         
                                                               80%, *P* = NS                                                                                                                                                                                                                                                
  PERTUSSIS                                                    54%                                                                                                                                                                                                                                                          
                                                               *vs*                                                                                                                                                                                                                                                         
                                                               54%, *P* = NS                                                                                                                                                                                                                                                
  Leonardi et al\[[@B19]\]                                     2015                                         Italy          Prospective        30 (mean age, 6 yr) CD/DMT1 *vs* 100 (13.6 yr) DMT1 *vs* 60 (8.6 yr) CD                                                                    HBV           53.3% *vs*           NA
  38.2% *vs*                                                                                                                                                                                                                                                                                                                
  50%, *P* \> 0.02                                                                                                                                                                                                                                                                                                          
  Sari et al\[[@B20]\]                                         2011                                         Turkey         Prospective        33 (mean age ± SD, 8.4 ± 3.6 yr) CD *vs* 62 (8.9 ± 3.6 yr) controls                                                                        HAV           21.2% (after 1 mo)   62.1% CD
  3% (after 7 mo)                                              21.8% controls:                                                                                                                                                                                                                                              
  *vs*                                                         HLA-DQ2                                                                                                                                                                                                                                                      
  22.6% (after 1 mo)                                           34.8% CD                                                                                                                                                                                                                                                     
  1.6% (after 7 mo)                                            9.7% controls:                                                                                                                                                                                                                                               
                                                               HLA-DR3                                                                                                                                                                                                                                                      
                                                               13.6% CD                                                                                                                                                                                                                                                     
                                                               4.8% controls                                                                                                                                                                                                                                                
                                                               HLA-DR7                                                                                                                                                                                                                                                      
  Schäppi et al\[[@B21]\]                                      2012                                         Switzerland    Prospective        14 (mean age 12.9 yr) treated CD *vs* 14 (12.9 yr) controls                                                                                Influenza     0                    50% CD:
  A/H1N1/09                                                    *vs*                                         HLA DQ2                                                                                                                                                                                                         
                                                               0                                            heterozygous                                                                                                                                                                                                    
                                                                                                            50% CD:                                                                                                                                                                                                         
                                                                                                            HLA DQ2                                                                                                                                                                                                         
                                                                                                            homozygous                                                                                                                                                                                                      
  Filippelli et al\[[@B24]\]                                   2016                                         Italy          Prospective        51 CD children at diagnosis                                                                                                                HBV           30.60%               23.50%
  HLA DQ2                                                                                                                                                                                                                                                                                                                   
  Omozygous                                                                                                                                                                                                                                                                                                                 
  13.70%                                                                                                                                                                                                                                                                                                                    
  HLA DQ2/DQ8                                                                                                                                                                                                                                                                                                               

HBV: Hepatitis B virus; CD: Celiac disease; HLA: Human leukocyte antigen; NA: Non available; DMT1: Diabetes mellitus type 1; NS: Not statistically significant; HAV: Hepatitis A virus; SD: Standard deviation.

Zingone et al\[[@B22]\] evaluated the response to HBV vaccine in relation to gluten consumption in three groups of patients with CD and in a control group: group A, adolescents on gluten-containing diet vaccinated at age 12 years in whom CD was diagnosed after vaccination; group B, adolescents vaccinated when 12-years old who were on GFD at the time of vaccination; and group C, patients who received HBV vaccine at birth; and group D, healthy subjects. An insufficient response to HBV immunization was observed in 43.9%, 34.8%, and 58.3% of CD patients in group A, B, and C, respectively, *vs* 8.3% of subjects in group D. Thus, the authors suggested that the immune response to HBV vaccine is independent of gluten exposure and that the human leukocyte antigen possibly act as the principal immunological determinant of poor responses to HBV vaccine in CD patients. Zingone et al\[[@B23]\] also investigated the duration of anti-HBs 11 years following primary vaccination and immune memory to HBV in adult individuals with CD who had been vaccinated when adolescents. They showed that the proportion of vaccinated persons with antibody titres ≥ 10 mIU/mL was less among CD patients than among controls. Finally, in a very recent paper Leonardi et al\[[@B19]\] comparing a group of patients affected by diabetes mellitus type 1 (DMT1) and CD and a group affected by DMT1 without CD (the HLA haplotype was similar in both groups), demonstrated a higher (though non-significant) proportion of non-responders, 53.3%, in the DMT1/CD group than in the DMT1 group, 38.2%; comparing the DMT1/CD group with CD group the authors found a similar percentage (53.3% *vs* 50%) of non-responders and this result supports the hypothesis that the efficacy of HBV vaccine can be further decreased by gluten, beyond the HLA system\[[@B19]\].

The effect of HAV vaccine in children with CD was studied by Sari et al\[[@B20]\]. After administration of inactivated HAV vaccine intramuscularly in a 2-dose schedule at 0 and 6 mo to 33 CD patients and healthy controls, the authors found that seroconversion rates at 1 mo were 78.8% and 77.4%, respectively; by 7 mo the rates were 97.0% and 98.4%. Therefore, they concluded that in children with CD, HAV vaccine produces a good immune response, almost the same as healthy controls, and that the routine HAV immunization protocol for healthy children may be utilized with success in these patients. A prospective investigation by Schäppi et al\[[@B21]\] about vaccine response in 14 pediatric patients with CD and controls matched for age and gender demonstrated that CD children achieved protective antibody titers comparable with the control group.

ROLE OF HLA IN IMMUNE RESPONSE
==============================

Immune response to vaccines has been found to be affected by several factors, but host genetic variations are thought to be the main cause for variable vaccine responsiveness\[[@B6]\]. The HLA alleles, holding in one of the most gene-dense, but most variable regions of human genome, namely the major histocompatibility complex region\[[@B44]\], are essential for determining the specificity of an individual's immune response\[[@B6]\].

As HLA molecules are part of the structural component for immune recognition by T-lymphocytes, polymorphisms in these molecules were expected to modulate antibody responses to vaccination\[[@B45]\]. The HLA are coded by the major histocompatibility complex group of genes located on chromosome six in the human genome and they are essential for determining the specificity of an individual's immune response\[[@B6]\]. There are three classes of HLA: HLA class I, class II and class III. Among them, HLA class II molecules have the task of presenting antigens to the T-lymphocytes from outside the cell. Antibody-producing B-cells are then stimulated to produce specific antibodies by these antigens\[[@B46]\]. HLA-DQ2 haplotype may be responsible for lack of induction of the Th2 response necessary for the promotion of the differentiation of B cells and the formation of memory B cells. HLA is believed to contribute significantly to the genetic susceptibility immune response variations to the vaccine\[[@B25]\]. Poor or non-responsiveness to HBV vaccine has been related to HLA DQ2, DR3, and DR7 alleles that are also linked to CD\[[@B25]-[@B27]\]. In particular, HLA genotype DQ2, present in 90%-95% of individuals with CD, may have a fundamental part in the predisposition to a weaker response to recombinant HBV vaccine. Inadequate or scarce HBsAg-specific T-helper cells, defective T-helper 1 and T-helper 2 cytokine release\[[@B7],[@B44]-[@B48]\], or reduced expression of cell-contact signal between activated T and B cells, such as CD40L\[[@B49]\] may also be responsible for the lack of response to HBsAg\[[@B50],[@B51]\]. Interleukin genotype (IL10, IL12, IL18) was related to the development of anti-HBs antibodies in response to HBsAg in hemodialysis patients\[[@B52],[@B53]\]. Chen et al\[[@B54]\] in 2011 found that anti-HBsAg response to HBV vaccination in healthy persons was closely related to 4 specific SNPs in the IL4, IL4RA, IL13 and toll-like receptor (TLR2) genes and suggested that variation in these structures may influence the persistence and degree of HBV vaccine-induced immune response\[[@B54]\].

Other studies suggested that compliance with a GFD is responsible for the effect of HBV vaccine in patients with CD\[[@B12]\]. Indeed, it has been hypothesized that gluten intake may be the cause of failed immunity after vaccination. Gluten may be responsible since both HBsAg protein fragments and gliadin peptides bind to HLA-DQ2 molecules inducing proliferation of T lymphocytes. Defective antibody production may result from competition between the proteins\[[@B48]\].

NEW STRATEGIES FOR HEPATITIS B VACCINATION IN CHILDREN WITH CELIAC DISEASE
==========================================================================

Inadequate effect of HBV immunization in youths affected by CD is a public health concern because those who fail to respond may become a reservoir of HBV infection. Thus, immune response to HBV vaccine needs to be studied in these patients. In order to prevent HBV infection in these patients and to achieve universal protection, new immunization strategies were proposed for patients with CD: the first is to administer booster HBV vaccine and/or higher doses given intramuscularly, the second is to use the intradermal route. The studies that have addressed these new immunization strategies in subjects with CD are summarized in Table [2](#T2){ref-type="table"}\[[@B12],[@B13],[@B55],[@B56]\]. Nemes et al\[[@B12]\] administered intramuscularly 20 μg of recombinant HBV vaccine as a booster to 37 non-responder CD children on GFD, and found that 36 out 37 (97.3%) had seroconversion 4 wk after vaccination. However, success with the booster vaccination after controlled GFD suggests that vaccination failure may be affected by disease activity. Few studies exist about HBV vaccine administered by intradermal route in patients with CD who do not respond to intramuscular recombinant vaccine. Leonardi et al\[[@B55]\] re-vaccinated 20 children and adolescents with CD using a 2 μg dose of recombinant intradermal HBV vaccine. At 4 wk, they found that 15 out 20 patients (75%) showed a protective titer of anti-HBs. Subsequently Leonardi et al\[[@B56]\] conducted a prospective, randomized study involving 58 CD patients, who had been vaccinated in infancy, but without protective HBV antibodies as demonstrated by blood analysis. They randomly administered a 2 μg booster dose of recombinant HBV vaccine by the intradermal route in 30 of these children, and a 10 μg dose of the same vaccine by the intramuscular route in 28 of them. Four weeks after the third booster dose, 90% of patients received the vaccine by the intradermal route and 96.4% of subjects received it by the intramuscular route showed a protective anti HBs titer. The authors concluded that both routes are effective in revaccinating CD patients, although the intradermal route may yield a significantly higher proportion of higher responders.

###### 

Seroconversion rate in children and adolescents with celiac disease after intramuscular or intradermal hepatitis B virus vaccination

  **Ref**.                   **Year**   **Country**   **Study design**   **Patients population and sample size**               **VAC Ag**   **Type of vaccine**   **Route**          **Number of boster doses**   **Seroconversion**
  -------------------------- ---------- ------------- ------------------ ----------------------------------------------------- ------------ --------------------- ------------------ ---------------------------- --------------------
  Nemes et al\[[@B12]\]      2008       Finland       Prospective        37 (mean age, 16.7 yr) non responders CD on GFD       HBV          Recombinant           IM                 1                            97.30%
  Ertem et al\[[@B13]\]      2010       Turkey        Prospective        28 (mean age ± SD, 12.4 ± 5.4 yr) non responders CD   HBV          Recombinant           IM                 3 doses of HBV vaccine       96.40%
  Leonardi et al\[[@B55]\]   2010       Italy         Prospective        20 non responders CD to IM vaccination                HBV          Recombinant           ID                 4                            90%
  Leonardi et al\[[@B56]\]   2012       Italy         Prospective        58 (mean age ± SD 9.8 ± 6.2 yr) non responders CD     HBV          Recombinant           30 ID *vs* 28 IM   3                            After first dose:
  ID: 76.7% *vs*                                                                                                                                                                                                  
  IM: 78.6%                                                                                                                                                                                                       
  After third dose:                                                                                                                                                                                               
  ID: 90% *vs*                                                                                                                                                                                                    
  IM: 96.4%                                                                                                                                                                                                       
  High responders                                                                                                                                                                                                 
  (anti-HBs \> 1000 IU/L):                                                                                                                                                                                        
  ID: 40%                                                                                                                                                                                                         
  IM: 7%, *P* \< 0.01                                                                                                                                                                                             

IM: Intramuscular; ID: Intradermal; VAC: Vaccine; Ag: Antigen; GFD: Gluten free diet; HBV: Hepatitis B virus; anti-HBs: Anti-hepatitis B surface.

The intradermal route may offer greater immunogenicity due to the straight contact between antigen and the immune system of the skin, also if smaller amounts of antigen are used\[[@B53]\]. Furthermore, determination of a skin reaction at the place of the intradermal injection might be a more economic policy to detect anti-HBs antibodies following the booster vaccine\[[@B54]\]. Economic studies suggest that substantial cost-saving benefits could be achieved employing a fraction of the intramuscular dose through the intradermal administration\[[@B57],[@B58]\].

CONCLUSION
==========

Present evidence supports the good immunogenicity of vaccines in children affected by CD with the exception of HBV. The available literature shows that HBV vaccine response is lower in subjects with CD. Some Authors hypothesize that the lack of response to HBV vaccination is related to specific HLA association while others argue that exposure to gluten at the time of vaccine administration may be responsible. Nonetheless, non-responsiveness to HBV vaccination in CD subjects is a serious public health problem because of the wide diffusion of CD, which affects about 1% of the European population. Consequently, new vaccination strategies have been proposed in order to reach complete protection, including administration of booster shots of HBV vaccine by the intramuscular or the intradermal *via*. An evaluation of the response to HBV vaccine should be implemented as a routine assessment in youths newly diagnosed CD who were previously vaccinated for HBV. When unresponsiveness occurs, revaccination utilizing the intradermal route determines a potentially higher immune response than the intramuscular route, even employing smaller doses, owing to the direct delivery of antigen to the skin immune system. Moreover, revaccination needs to be done following the decline of specific antibodies, which commonly emerges after approximately 1 year of GFD.
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